Mylan (MYL), Actavis (ACT) Continue Lower Following CVS/Cardinal Health Agreement
Tweet
Share
E-mailGet Alerts CVS Hot Sheet
Price: $104.66 +2.74%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 3.3%
Revenue Growth %: +1.2%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 3.3%
Revenue Growth %: +1.2%
Join SI Premium – FREE
Mylan (Nasdaq: MYL), Actavis (NYSE: ACT) are lower Tuesday following CVS (NYSE: CVS) and Cardinal Health (NYSE: CAH) reaching a new generic sourcing entity agreement with Cardinal Health, which is said to be the largest in the U.S.
Mylan is down 3.4 percent, while Actavis is down 2.5 percent.
Mylan is down 3.4 percent, while Actavis is down 2.5 percent.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Doncasters (DPC) indicating open around $40, IPO priced at $33
- Morpheus shorts Velo3D: 'parlayed a failed SPAC and a sham SpaceX relationship into a fortune'
- Pentagon To Allow Critical Minerals Plants On Us Army Bases - Bloomberg
Create E-mail Alert Related Categories
Insiders' Blog, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
